Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs

被引:328
作者
Swanton, Charles
Marani, Michela
Pardo, Olivier
Warne, Patricia H.
Kelly, Gavin
Sahai, Erik
Elustondo, Frederic
Chang, Jenny
Temple, Jillian
Ahmed, Ahmed A.
Brenton, James D.
Downward, Julian
Nicke, Barbara
机构
[1] Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England
[2] Canc Res UK, London Res Inst, Bioinformat & Biostat Labs, London WC2A 3PX, England
[3] Canc Res UK, London Res Inst, Tumour Cell Biol Labs, London WC2A 3PX, England
[4] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England
[5] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
[6] Cambridge Res Inst, Funct Genom Drug Resistance Lab, Cambridge CB2 2XZ, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/j.ccr.2007.04.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytotoxic drug resistance is a major cause of cancer treatment failure. We report an RNA interference screen to identify genes influencing sensitivity of different cancer cell types to chemotherapeutic agents. A set of genes whose targeting leads to resistance to paclitaxel is identified, many of which are involved in the spindle assembly checkpoint. Silencing these genes attenuates paclitaxel-induced mitotic arrest and induces polyploidy in the absence of drug. We also identify a ceramide transport protein, COL4A3BP or CERT, whose downregulation sensitizes cancer cells to multiple cytotoxic agents, potentiating endoplasmic reticulum stress. COL4A3BP expression is increased in drug-resistant cell lines and in residual tumor following paclitaxel treatment of ovarian cancer, suggesting that it could be a target for chemotherapy-resistant cancers.
引用
收藏
页码:498 / 512
页数:15
相关论文
共 41 条
  • [1] Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling
    Alaoui-Jamali, MA
    Dupré, I
    Qiang, H
    [J]. DRUG RESISTANCE UPDATES, 2004, 7 (4-5) : 245 - 255
  • [2] Genome-wide survey of protein kinases required for cell cycle progression
    Bettencourt-Dias, M
    Giet, R
    Sinka, R
    Mazumdar, A
    Lock, WG
    Balloux, F
    Zafiropoulos, PJ
    Yamaguchi, S
    Winter, S
    Carthew, RW
    Cooper, M
    Jones, D
    Frenz, L
    Glover, DM
    [J]. NATURE, 2004, 432 (7020) : 980 - 987
  • [3] Prolonged mitosis versus tetraploid checkpoint - How p53 measures the duration of mitosis
    Blagosklonny, MV
    [J]. CELL CYCLE, 2006, 5 (09) : 971 - 975
  • [4] Mutations of mitotic checkpoint genes in human cancers
    Cahill, DP
    Lengauer, C
    Yu, J
    Riggins, GJ
    Willson, JKV
    Markowitz, SD
    Kinzler, KW
    Vogelstein, B
    [J]. NATURE, 1998, 392 (6673) : 300 - 303
  • [5] A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
    Carter, Scott L.
    Eklund, Aron C.
    Kohane, Isaac S.
    Harris, Lyndsay N.
    Szallasi, Zoltan
    [J]. NATURE GENETICS, 2006, 38 (09) : 1043 - 1048
  • [6] Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Chang, JC
    Wooten, EC
    Tsimelzon, A
    Hilsenbeck, SG
    Gutierrez, MC
    Elledge, R
    Mohsin, S
    Osborne, CK
    Chamness, GC
    Allred, DC
    O'Connell, P
    [J]. LANCET, 2003, 362 (9381) : 362 - 369
  • [7] Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel
    de las Alas, MM
    Christen, RD
    Gately, DP
    Weiner, DE
    Benbatoul, K
    Kirmani, S
    D'Agostino, HR
    Plaxe, SC
    Darrah, D
    McClay, EF
    Aebi, S
    Howell, SB
    Los, G
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (05) : 381 - 388
  • [8] Parallel chemical genetic and genome-wide RNAi screens identify cytokinesis inhibitors and targets
    Eggert, US
    Kiger, AA
    Richter, C
    Perlman, ZE
    Perrimon, N
    Mitchison, TJ
    Field, CM
    [J]. PLOS BIOLOGY, 2004, 2 (12) : 2135 - 2143
  • [9] Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer
    Ein-Dor, L
    Zuk, O
    Domany, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (15) : 5923 - 5928
  • [10] Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs
    Gouazé, V
    Liu, YY
    Prickett, CS
    Yu, JY
    Giuliano, AE
    Cabot, MC
    [J]. CANCER RESEARCH, 2005, 65 (09) : 3861 - 3867